Dihydroartemisinin-piperaquine for the routine treatment of uncomplicated malaria in Northern Ghana

Simple item page
dc.contributor.authorOduro, Abraham R.en_US
dc.contributor.authorChatio, Samuelen_US
dc.contributor.authorAyamba, Emmanuelen_US
dc.contributor.authorAnyorigiya, Thomasen_US
dc.contributor.authorBinka, Freden_US
dc.contributor.authorLucas, Amenga-Etegoen_US
dc.date.accessioned2020-05-06T08:34:21Z
dc.date.available2020-05-06T08:34:21Z
dc.date.issued2020-01
dc.description.abstractBackground:Dihydroartemisinin-piperaquine is a first line treatment for uncomplicated malaria in Ghana. A facility-based study was undertaken to examine the effectiveness of thetreatment in the routine health care system.Methods:The study was undertaken at the Navrongodemographic surveillance area. Patients presenting with acute febrile illness were enrolled after informed consented and confirmation by microscopy. Patients were randomized into supervised group who received treatment under direct observation and unsupervised group which had only the first treatment given under supervision. Treatment was according to bodyweight and 42 days follow-up was undertaken.Results:A total of 194 patients were enrolled; 54.1% were females and 51% had supervised treatment. The median age and weight were 6.7 years and 20.0kg respectively. Mean baseline temperature, haemoglobin concentration and parasite density were, 37.6oC, 11.1 g/dl and 11,098 parasites per microliter of blood respectively. Study completion rate was 93.3%, day 42 polymerase chain reaction-unadjusted adequate clinical and parasitological responses rate (ACPR) was 93.4% by evaluable and 87.1 % by intention-to-treat (ITT). The day 42 ACPR by evaluable was 92.3% in the supervised arm compared to 94.4% in the unsupervised arm. The day 42 ACPR by ITT was 85.7% in the supervised and 88.5% in the unsupervised arms. The fever resolution and haemoglobin concentration changes for the two arms were similar.Conclusions: The results show that dihydroartemisinin-piperaquine iseffective and good first-line antimalarial in the routine health delivery systemen_US
dc.identifier.affiliationsNavrongo Health Research Centre, Ghana Health Service, Navrongo, Ghanaen_US
dc.identifier.affiliationsUniversity of Health and Allied Sciences, School of Public Health, Ho, Ghanaen_US
dc.identifier.affiliationsWest African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Legon, Ghanaen_US
dc.identifier.citationOduro Abraham R., Chatio Samuel, Ayamba Emmanuel, Anyorigiya Thomas, Binka Fred, Lucas Amenga-Etego. Dihydroartemisinin-piperaquine for the routine treatment of uncomplicated malaria in Northern Ghana. International Journal of Clinical Trials. 2020 Jan; 7(1): 1-10en_US
dc.identifier.issn2349-3240
dc.identifier.issn2349-3259
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/200947
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber1en_US
dc.relation.volume7en_US
dc.source.urihttps://dx.doi.org/10.18203/2349-3259.ijct20200200en_US
dc.subjectEffectivenessen_US
dc.subjectDihydroartemisinin-piperaquineen_US
dc.subjectUncomplicated malariaen_US
dc.subjectGhanaen_US
dc.titleDihydroartemisinin-piperaquine for the routine treatment of uncomplicated malaria in Northern Ghanaen_US
dc.typeJournal Articleen_US
Files
Collections
International Journal of Clinical Trials